WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 11:00 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clo ...

AI卷起的财富风暴。 出品 | 虎嗅科技医疗组 作者 | 陈广晶 编辑 | 苗正卿 头图 | AI生成 以下文章来源于AGI接口 ，作者陈广晶 AGI接口 . 花样翻新的赛博"大白"（ 电影《超能陆战队》中的健康助手 ）正涌进患者手机。 刚过35岁的肖颖，年初在某大医院生了宝宝。出院的时候，护士再三叮嘱她下载一个APP，在这 个软件上可以挂互联网医院的号，关于母亲和婴儿的任何问题都可以在线提问。 这个APP，肖颖早就下载了，除了线上问诊、挂号、体检、档案管理，疫苗接种预约都可以在这 个软件上进行。出院后，正好赶上流感爆发，她和婴儿相继发烧，软件上的AI报告解读，健康咨 询，缓解了肖颖初为人母的焦虑。 与肖颖类似，越来越多出院患者、门诊患者在医院、医生的介绍下拥有了赛博"大白"，还不止一 个。 在其背后，面向大众的医疗AI服务呈现出爆发的趋势。业界盘点的当下最热门的20大医疗AI场景 中，面向大众的"报告解读"、"智能导诊"排在前两位，远超与医疗服务关系密切的"合理用药""医 保控费"等。 覆盖看诊前轻问诊、出院后随访等内容的AI健康管理产品更是层出不穷，已经聚集了上亿用户的 互联网大厂在其中更是激战正酣，京东 ...

Core Viewpoint - Treatment.com AI Inc. has engaged two firms, 45 Degrees and Investment Publishing, to enhance its digital marketing and investor relations efforts, aiming to increase awareness and reach within the healthcare sector [1][4]. Group 1: Engagement with 45 Degrees - Treatment has contracted 45 Degrees for a six-month marketing engagement starting July 18, 2025, with a total fee of USD $180,000, payable in two installments [2]. - The marketing services include Google Ads, social media, and video interview distribution, with an option to extend the engagement on a month-to-month basis for USD $25,000 [2]. - Treatment has issued 400,000 stock options to the principal of 45 Degrees, exercisable at $0.45 per share for three years [3]. Group 2: Engagement with Investment Publishing - Treatment has engaged Investment Publishing for an initial one-year term to enhance its investor relations strategy, focusing on increasing company awareness [4]. - The engagement includes public relations efforts, educational content, and direct outreach through various digital platforms [4]. - Investment Publishing will also receive 400,000 stock options, exercisable at $0.45 per share for three years [4]. Group 3: Additional Option Grants - Treatment has granted an additional 400,000 stock options to certain arm's length consultants, also exercisable at $0.45 per share for three years [5]. Group 4: Company Overview - Treatment.com AI utilizes artificial intelligence to improve healthcare sector efficiencies, with a comprehensive AI engine known as the Global Library of Medicine (GLM) [6]. - The GLM provides over 10,000 expert medical reviews and supports healthcare professionals by reducing administrative burdens and improving patient care [6].

Core Insights - Biotricity Inc. has reported significant financial improvements for fiscal year 2025, showcasing a transformation driven by technology and operational efficiencies [2][8][9] Financial Performance - FY25 revenue increased by 14.3% year-over-year to $13.8 million, up from $12.1 million in FY24 [9] - Gross margin improved to 76.6% in FY25, compared to 69.3% in FY24, attributed to increased recurring technology fee revenue and operational efficiencies [8][9] - The net loss for FY25 decreased by 20% year-over-year to $11.9 million, or $0.56 per share, down from a net loss of $14.9 million, or $1.66 per share, in FY24 [9] - Positive Adjusted EBITDA of $438,260 was achieved in Q4 FY25, marking the first time in the company's history to reach EBITDA positivity [8][9] Operational Highlights - Recurring Technology Fees rose by 12% year-over-year to $12.6 million, significantly outpacing Device Sales revenue [7] - Operating expenses were reduced by 24.5% year-over-year, contributing to improved financial metrics [8] - The company is on track to achieve EBITDA breakeven and long-term profitability in FY26 [2][8] Strategic Developments - Biotricity has expanded its Cardiac AI Cloud platform through strategic partnerships, enhancing its market reach to approximately 90% of hospitals in the U.S. [4][3] - The company is pursuing FDA clearance for its AI clinical model, which is expected to revolutionize medical diagnostics and chronic care management [3][4] - Collaborative partnerships established during FY25 and FY26 are aimed at capitalizing on new market channels and value-based care programs [4] Market Position - Biotricity is positioned within a total addressable market of $35 billion, focusing on innovative and accessible cardiac care solutions [15] - The company has secured strategic alliances with three of the top Group Purchasing Organizations (GPOs), representing a significant portion of U.S. hospitals [15]

CARMEL, Ind., July 17, 2025 /PRNewswire/ -- Syra Health (OTCQB: SYRA), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today it has been awarded a new contract with a major insurance provider to staff registered nurses to support specific health plans.Under the one-year agreement, worth up to $2.1 million, Syra Health will provide medical management nurses to work with healthcare providers and plan members. The nurses will as ...

SOMERSET, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, today announced the launch of its fully integrated, AI-driven dermatology EHR, designed to streamline clinical workflows and collections, while enhancing patient engagement and improving financial outcomes for dermatology practices. "Our fully integrated, AI-driven dermatology ...

Core Viewpoint - OptimizeRx Corp. is set to discuss its second quarter financial results for the period ending June 30, 2025, during a conference call scheduled for August 7, 2025 [1][2]. Company Overview - OptimizeRx is a leading healthcare technology company that focuses on connecting life science brands with patients and healthcare providers through innovative solutions [4]. - The company utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to enhance engagement and improve patient outcomes [4]. - OptimizeRx is committed to privacy-safe, patient-centric technology, ensuring impactful interactions that deliver therapies to the right patients at the right time [5]. Conference Call Details - The conference call will take place on August 7, 2025, at 4:30 p.m. Eastern Time, with a question-and-answer session following the management's presentation [2]. - Participants can join the call via toll-free and international numbers, and a webcast will also be available [2]. - A replay of the call will be accessible for 12 months on the company's investor relations website [3].

SOMERSET, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) ("CareCloud" or the "Company"), a leader in AI-powered healthcare technology and revenue cycle management solutions for medical practices and health systems nationwide, will release its financial results for the second quarter ended June 30, 2025 before the market opens on Tuesday, August 5, 2025. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time. The live webcast of the conference ca ...

This AI Founder Became A Billionaire By Building ChatGPT For Doctors https://t.co/BOlZ5TfypI https://t.co/BOlZ5TfypI ...

NAPLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology and patient engagement solutions, today announced that it has engaged Meridian Group, a premier strategic advisory firm, to assist in identifying and securing strategic partnerships that can accelerate the adoption of the HealthLynked platform, significantly increase revenue, and position the company for long-term growth—including a potential uplisting to the Nasdaq Capital Market. A ...